China Pharma Holdings Stock Performance
| CPHI Stock | USD 0.20 0.01 5.26% |
China Pharma has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -1.23, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning China Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, China Pharma is expected to outperform it. China Pharma Holdings right now shows a risk of 7.04%. Please confirm China Pharma Holdings jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if China Pharma Holdings will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in China Pharma Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain technical indicators, China Pharma may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Last Split Factor 1:5 | Last Split Date 2024-03-06 |
1 | Avenacy to Share Companys Year One Progress at CPHI Milan 2024 | 09/23/2024 |
2 | StockNews.com Initiates Coverage on China Pharma | 10/01/2024 |
3 | ClorNovir by Dr. Ferrer BioPharma Named Finalist at CPHI Pharma Awards 2024 for Breakthrough COVID-19 and Post-COVID Care | 10/09/2024 |
4 | Kexing Biopharm made its appearance at CPHI Milan 2024 Launch Ceremony for Apexelsin in EU market Successfully done | 10/17/2024 |
5 | Kexing Biopharm CPHI Milan 2024 Apexelsin | 10/18/2024 |
6 | China Pharma Receives New Coverage from Analysts at StockNews.com | 10/24/2024 |
7 | Riassunto Produzione avanzata, portata globale e servizi semplificati Asymchem lascia il segno a CPHI Milano 2024 | 10/31/2024 |
| Begin Period Cash Flow | 2 M |
China |
China Pharma Relative Risk vs. Return Landscape
If you would invest 21.00 in China Pharma Holdings on August 24, 2024 and sell it today you would lose (1.00) from holding China Pharma Holdings or give up 4.76% of portfolio value over 90 days. China Pharma Holdings is currently generating 0.157% in daily expected returns and assumes 7.0361% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than China, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
China Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for China Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as China Pharma Holdings, and traders can use it to determine the average amount a China Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0223
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CPHI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.04 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.16 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average China Pharma is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of China Pharma by adding it to a well-diversified portfolio.
China Pharma Fundamentals Growth
China Stock prices reflect investors' perceptions of the future prospects and financial health of China Pharma, and China Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on China Stock performance.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 8.8 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Price To Earning | (0.89) X | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.01 M | ||||
| Gross Profit | 349.27 K | ||||
| EBITDA | 8.44 K | ||||
| Net Income | (3.08 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 2.62 % | ||||
| Current Ratio | 0.75 X | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | (699.69 K) | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 3.69 M | ||||
| Total Asset | 16.47 M | ||||
| Retained Earnings | (39.29 M) | ||||
| Working Capital | (823.73 K) | ||||
| Current Asset | 20.99 M | ||||
| Current Liabilities | 12.95 M | ||||
About China Pharma Performance
By evaluating China Pharma's fundamental ratios, stakeholders can gain valuable insights into China Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if China Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if China Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 181.36 | 248.04 | |
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.29) | (0.27) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.41) | (0.39) |
Things to note about China Pharma Holdings performance evaluation
Checking the ongoing alerts about China Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for China Pharma Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| China Pharma had very high historical volatility over the last 90 days | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| China Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of China Pharma shares are held by company insiders | |
| Latest headline from businesswire.com: Riassunto Produzione avanzata, portata globale e servizi semplificati Asymchem lascia il segno a CPHI Milano 2024 |
- Analyzing China Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether China Pharma's stock is overvalued or undervalued compared to its peers.
- Examining China Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating China Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of China Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of China Pharma's stock. These opinions can provide insight into China Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for China Stock analysis
When running China Pharma's price analysis, check to measure China Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China Pharma is operating at the current time. Most of China Pharma's value examination focuses on studying past and present price action to predict the probability of China Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China Pharma's price. Additionally, you may evaluate how the addition of China Pharma to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |